Status: Enrolling
Investigator: Aparna Kamat
Study Coordinator: Jaya Kamath
Phone: 713.441.6616
The study evaluates the response to treatment with Ribociclib and Letrozole in patients with recurrent low grade serous cancer of the ovary, fallopian tube or peritoneum. ... Read more >
Status: Open Not Enrolling
Investigator: Raj Satkunasivam
Study Coordinator: Cinthya Yesenia Obando Perez
Phone: 346.238.6123
This randomized phase III trial studies Tokyo-172 strain bacillus Calmette-Guerin (BCG) solution with or without a vaccination using Tokyo-172 strain BCG to see how well it works compared with TICE BCG solution in treating patients with bladder ... Read more >
Status: Enrolling
Investigator: Tarrik Zaid
Study Coordinator: Jaya Kamath
Phone: 713.441.6616
This randomized phase III trial studies radiation therapy and cisplatin with triapine to see how well they work compared to the standard radiation therapy and cisplatin alone in treating patients with newly diagnosed stage IB2, II, or IIIB-IVA c ... Read more >
Status: Enrolling
Investigator: Aparna Kamat
Study Coordinator: Jaya Kamath
Phone: 713.441.6616
The purpose of this study is to prospectively collect de-identified biological samples and data from women with a known pelvic mass, in order to validate ovarian cancer specific glycoproteomic signatures in the blood based on histologically conf ... Read more >
Status: Enrolling
Investigator: Aparna Kamat
Study Coordinator: Jaya Kamath
Phone: 713.441.6616
This phase II/III trial studies how well pegylated liposomal doxorubicin hydrochloride with atezolizumab and/or bevacizumab work in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has come back (recurrent). Drug ... Read more >
Status: Enrolling
Investigator: Raj Satkunasivam
Study Coordinator:
Phone:
This is a Phase 3, Multicenter, Double-blind, Randomized, Placebo-Controlled Trial to evaluate the efficacy of Infigratinib in adult patients with invasive urothelial carcinoma with susceptible FGFR3 genetic alterations (mutations, and gene fusi ... Read more >
Status: Enrolling
Investigator: Jorge Darcourt
Study Coordinator: Syed Muhammad Saad
Phone: 281.276.5263
This is an international, multi-center, open-label, phase II study in patients with metastatic urothelial cancer after failure of platinum-based regimen or anti-PD-1 /PD-L1 based immunotherapy. At least 140 patients are anticipated to be enrolle ... Read more >
Status: Enrolling
Investigator: Aparna Kamat
Study Coordinator: Jaya Kamath
Phone: 713.441.6616
Drugs used in chemotherapy, such as cisplatin, paclitaxel, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kil ... Read more >
Status: Enrolling
Investigator: Jorge Darcourt
Study Coordinator:
Phone:
The purpose of this study is to compare any good and bad effects of using radium-223 along with docetaxel chemotherapy treatment versus using docetaxel alone. ... Read more >
Status: Enrolling
Investigator: Kirk Heyne
Study Coordinator:
Phone:
This is a multicenter Phase 1b, open-label study to assess safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of cabozantinib taken in combination with atezolizumab in subjects with multiple tumor types, including advanced uro ... Read more >
Status: Open Not Enrolling
Investigator: Jorge Darcourt
Study Coordinator: Syed Muhammad Saad
Phone: 281.276.5263
This is a randomized, open-label, multicenter Phase 2/3 study to evaluate the efficacy and safety of rogaratinib (BAY 1163877) compared to chemotherapy in patients with FGFRpositive locally advanced or metastatic urothelial carcinoma who have re ... Read more >
Status: Enrolling
Investigator: Raj Satkunasivam
Study Coordinator: Cinthya Yesenia Obando Perez
Phone: 346.238.6123
Primary Purpose: Treatment ... Read more >
